Table 4.
Therapeutic and safety monitoring tests completion
| Drug class | Monitoring parameter | Frequency | Test done n (%) | Test not done n (%) |
|---|---|---|---|---|
| Antidiabetics, oral | HbA1c | Baseline | 64 (89) | 8 (11) |
| Every 6 months, or more frequently | 46 (64) | 26 (36) | ||
| Renal functiona | Baseline | 42 (58) | 30 (42) | |
| SMBG | Recommended but not required | 60 (83) | 12 (17) | |
| Antihypertensives | SMBP | Once weekly, or more frequently | 76 (42) | 103 (57) |
| Bisphosphonates | DXA score | Baseline | 23 (96) | 1 (4) |
| 1–2-year interval | 11 (46) | 12 (54) | ||
| Insulin | SMBG | ≥3 times daily | 15 (79) | 4 (21) |
| HbA1c | Baseline | 16 (84) | 3 (16) | |
| Every 6 months, or more frequently | 16 (84) | 3 (16) | ||
| Statins | CPK | Baseline | 27 (25) | 79 (75) |
| LFT | Baseline | 68 (64) | 38 (36) | |
| Yearly | 69 (65) | 37 (35) | ||
| Thyroid replacement therapy (levothyroxine, triiodothyronine) | TSH/T4 | Baseline | 24 (100) | 0 |
| Yearly when stabilized | 23 (96) | 1 (4) |
Note:
a
Renal function monitoring is only required with metformin therapy and not with all oral antidiabetics.
Abbreviations: CPK, creatine phosphokinase; DXA, dual-energy X-ray absorptiometry; HbA1c, glycosylated hemoglobin; LFT, liver function tests; SMBG, self-monitoring of blood glucose; SMBP, self-monitoring of blood pressure; T4, thyroxine; TSH, thyroid stimulating hormone.